Although its underlying mechanisms are poorly understood, data comparing each of the four dengue virus serotypes suggest that in vitro antibody-dependent infection enhancement is a reproducible and measurable phenomenon related to other serological measures of antibody-virus binding. Information characterizing infection enhancement may provide clues to disease pathogenesis for dengue and other viruses that exhibit antibody-enhanced infection. We propose criteria for the detection and quantification of in vitro antibodydependent enhancement of flavivirus infection based on observations using all four dengue virus serotypes, macrophage-like cell lines and human peripheral blood monocytes, and various immune sera and monoclonal antibodies. It is proposed that antibody-dependent infection enhancement is defined by the following findings: (i) significantly increased virus production is measured in quantitative assays at different points on the growth curve; (ii) assays of the virus output of cells infected with mixtures of constant amounts of virus and serial dilutions of the pre-existing antibody source produce characteristic 'enhancement profiles' of rising and falling virus output over at least a 10-3-fold dilution range; (iii) for each enhancing antibody source the dilution producing maximal infection enhancement is related to other serological measures of binding to the envelope, or another virus component; (iv) infection enhancement is detected with different antibody sources and virus strains (when available) tested over a range of m.o.i.; (v) other causes of enhanced virus production are ruled out.
Introduction
Antibody-dependent enhancement of virus infection (ADE) is an in vitro phenomenon observed with many different RNA and DNA viruses. Strong circumstantial evidence suggests that ADE may be linked to some cases of severe dengue disease. The theoretical possibility that dengue vaccine-induced immunity might potentiate severe dengue disease has delayed vaccine development and human testing of candidate vaccines produced by both the World Health Organization and the U.S. Department of Defense. Recently, the possibility that ADE is involved in human immunodeficiency virus (HIV) disease pathogenesis has raised concerns about development of these vaccines as well. Some critics have called for cessation of such vaccine work. Problems with the data that give rise to these conclusions (Robinson et al., 1987 (Robinson et al., , 1988a Gras et al., 1988; Homsy et al., 1988; Takeda et al., 1988) underscore the need for standard measurement criteria for establishing and quantifying ADE. Because of inadequacies with methodology, these reports are difficult to interpret. In some, enhanced HIV growth was minimal (Gras et al., 1988; Takeda et al., 1988) , or merely recorded as decreased time to development of maximal output of virus antigen, or linked to such cofactors as complement or hypothetical nonantibody components in the eluates of sera passed through IgG affinity columns (Robinson et al., 1988a, b) . No report measured input and output of infectious virions, or distinguished ADE from increased virus production associated with competition for antibody or for CD4 receptor sites between infectious virus and noninfectious virus components in the virus stock, and most did not rule out a protective effect of antibody on thermal decay of the virus. Furthermore, lacking objective criteria for detecting and quantifying ADE these investigators, as well as others documenting ADE with different viruses, have reported such different ADE outcomes as magnitude of enhanced virus production, 'fold-enhancement' of virus production, the single antibody dilution at which maximum virus production or fold-enhancement occurs, or simply the decrease in time to maximal output of virus antigen. Criteria for detection and quantification of ADE have not yet been proposed 0000-9636 © 1990 SGM for any virus system. Lack of such standard criteria confounds evaluation of ADE studies, comparison of data from different groups and insights into disease pathogenesis.
Although there is no certainty that the basis of ADE is the same for different viruses for which it has been demonstrated, in undertaking this descriptive study of ADE with dengue viruses (DEN) we reasoned that an attempt to define and measure the observable parameters of ADE as produced in vitro with flaviviruses, with which our laboratory and others have had over 15 years of experience, and which are widely accepted as exhibiting in vitro ADE, offered the best starting point for more fully characterizing the nature of this serological phenomenonon for other viruses.
Methods
Virus strains. Standard tissue culture-adapted strains of South-east Asian origin were used: DEN-1 (16007), DEN-2 (16681), DEN-3 (16562) and . In the growth curve experiments we also used low-passage Thai DEN-2 isolates designated D80-141 and D80-280 (Morens et al., 1987a) , associated with grade III dengue shock syndrome (DSS) and grade I dengue haemorrhagic fever (DHF), respectively.
Antibody sources. Cord blood sera CB 23627, CB 23785, CB 23822 and CB 23824 from South-east Asian mothers include those previously described (Halstead et al., 1983) . For all except the growth curve experiments, the cord blood sera were pre-incubated with virus in eight serial fourfold dilutions, beginning at a dilution of 1 : 80. Post-infection sera from rhesus monkeys W-22 and W-35, immune to DEN-2 and DEN-4, respectively, were tested at a single dilution of 1 : 500, known to cause ADE with DEN-2 strain 16681. DEN-2-derived monoclonal antibody 1B10 (Gentry et al., 1982) and DEN-4 monoclonal antibody UH-2B4 (Morens et al., 1987b) are envelope-binding and flavivirus group-reactive in plaque reduction neutralization (PRNT) and haemagglutination inhibition (HI) tests. The reciprocal monoclonal ascitic fluid PRNT titres in BHK titrations (Morens et al., 1985) against the same strains of DEN-I, -2, -3 and -4 were 40, 70, 35 and 60, respectively for UH-2B4 and /> 640, /> 2560, /> 2560 and >t 640, respectively for 1BI0. Serial dilutions of myeloma ascitic fluid P3X63Ag8.653, referred to as P3, were used as a control ascitic fluid source. For the growth curve experiments in human peripheral blood leukocytes (PBLs), flavivirus non-immune human serum GT1 and immune cord blood serum CB 23822 were used at 1 : 1000 dilution, a dilution known previously to cause ADE with CB 23822 and a variety of DEN-2 strains.
Human peripheral blood leukocytes. PBLs used in the growth curve experiments were those of flavivirus non-immune donor GT 1, who also provided negative control serum for other purposes noted above. Venous blood was separated on a Ficoll-Hypaque gradient (Boyum, 1971) .
ADE assays. Semi-micro ADE assays were conducted in P-388D1 macrophages (Halstead etal., 1983) and assayed for virus content in the BHK suspension assay (Morens et al., 1985) . After determination of optimal test conditions in preliminary studies, sera were diluted in 10-fold steps from 10 -2 to 10 -a with monoclonal antibodies standardized for protein concentration (1 mg/ml) and diluted from 10 -2 to 10 -9, and the reaction mixtures were added to freshly split non-trypsinized, unwashed macrophages at an m.o.i, of 0-05. In the m.o.i, experiments, m.o.i, was varied between 0.01 and 0-25. The cells were incubated at 37 °C, virus was harvested by freezing and thawing at 96 and 120 h and titrated immediately to endpoint. The optimal harvest time was chosen by examining pre-test growth curves of antibody-enhanced and unenhanced virus (data not shown). With one exception, all reported results are those of 96 h harvests. Because the DEN-1 / 1B 10 pairing had poor growth at 96 h on two of the replicate tests, the 120 h harvests are reported for it. Assays with all four DEN serotypes were conducted in parallel on each of four occasions to obtain replicate data, each day using successive passages of the same macrophages with the same numbers of p.f.u, of each serotype as determined by BHK suspension assay titration (Morens et al., 1985) . For the growth curve studies 1.5 x 107 viable mononuclear ceils were added to 0.1 ml of appropriately diluted serum and tested at an m.o.i, of 0-05 (for DEN-2 strains D80-141 and D80-280) or 0.01 (for DEN-2 strain 16681) as previously described (Halstead et al., 1983) , with freeze-thaw harvesting on days 0, 3, 4 and 5 and titration in the BHK suspension assay (Morens et al., 1985) .
Statistical tests. Statistical significance of increased virus growth was calculated by the method of Detre & White (1970) .
Results and Discussion

Quantitative assays of increased virus production at different points on the growth curve
In DEN-2 growth curve studies, growth of each of 14 DEN-2 strains tested in human PBLs was undetectable after incubation and wash on day 0 and rose in titre over days 3, 4 and 5 of culture. Representative growth curves are shown in Fig. 1 . This pattern appears to be typical of DEN-2 growth in mononuclear cells (Halstead et al., 1976; Theofilopoulos et aL, 1976) . In all cases, antibodysupplemented virus production is significantly greater than unsupplemented virus production at each day after infection. Thus in the dengue/PBL system, ADE does not appear to be a transient phenomenon that might be missed if assays of virus production were imperfectly timed.
Enhancement profiles
In a preliminary report we described certain characteristics of ADE with DEN-2 (Morens et al., 1987a) . In this study we further characterized ADE with all four DEN serotypes and DEN monoclonal antibodies. Despite standardization of virus p.f.u, in BHK suspension titrations (Morens et al., 1985) , in the comparison studies using the DEN monoclonal antibodies there was different background growth of the four strains in the enchancing system of P-338D1 macrophages. The mean output p.f.u, for all tests with all of the serial P3 dilutions combined showed no background growth (< 0.15 p.f.u. per ml) of DEN-3 and DEN-4, low growth of DEN-1 (14 p.f.u, per ml) and substantial growth of DEN-2 (7212 p.f.u, per ml; Fig. 2 ). Despite these growth differences, infection with each DEN serotype was greatly enhanced by each of the monoclonal antibodies, the magnitude of enhancement for each virus being 102-to 103-fold above background, or above virus growth at the initial antibody dilution tested (10 -2 ) when background growth was not detected (Fig. 2) . Consistent with preliminary DEN-2 observations (Morens et al., 1987a) , plots of the growth of all four DEN serotypes as a function of serial dilution of pre-incubated antibody show a characteristic 'profile' of rising, peaking and declining virus production over a 10 -3-to 10-S-fold dilution range. The profiles for all four serotypes with both monoclonal sources appear similar. Each of the monoclonal antibodies is both neutralizing and enhancing, depending upon the concentration at which it is pre-incubated with constant amounts of virus. At least four measurable features of the ADE profiles may reflect different aspects of its underlying mechanisms. These are (i) the dilution range of antibody over which ADE occurs, (ii) the left-or right-shift of the ADE profile along the x-axis of antibody concentration, (iii) the absolute magnitude of enhanced virus production and (iv) the degree to which virus production is enhanced by antibody ('fold-enhancement'). For all four DEN serotypes studied with the two flavivirus group-reactive monoclonal antibodies, antibody UH-2B4 produced ADE over a more extended dilution range (about 10 -6-fold) than did 1B10 (about 10-4-fold). The detection of ADE after a 10 -6 serum dilution was surprising in view of the presumed scarcity of the IgG molecules added to the reaction mixtures. This virus-enhancing difference could reflect an antibody binding property, for example high avidity or affinity for a critical epitope. Highly infectious or enhanceable subpopulations of virus seems an unlikely explanation since the phenomenon was seen with all four DEN serotypes. Also unlikely is the possibility that despite cross-neutralization identity the two monoclonal antibodies are detecting different flavivirus group epitopes.
The magnitude of monclonal antibody-enhanced production of DEN-1, -3 and -4, all of which had similar background growth, was similar (Fig. 2 ). DEN-2 had both higher background growth and higher monoclonal antibody-enhanced growth, presumably reflecting some intrinsic but unidentified viral attachment, internalization or replicative capacity. However for each of the four dengue serotypes 'fold-enhancing' abilities of the properly diluted antibody sources were about the same regardless of the growth ability of the uncomplexed virus in the same system, which varied over an approximate 105 range. The effect of ADE on ceil sensitivity to infection is largely unexplored. If the cell receptor for the four serotypes is identical (this is unproven), higher unenhanced and antibody-enhanced DEN-2 production could reflect a binding property of the virus and its receptor, e.g. DEN-2 cell attachment sites on the envelope glycoprotein could be more accessible and thus more likely to bind to the cell receptor.
An unexpected finding was that monoclonal antibody UH-2B4 caused higher DEN-2 production than 1B10 (Fig. 2b) , but roughly the same virus production with the other DEN serotypes. From the 10 -2 to 10 -6 dilutions, DEN-2 growth was 12-to 400-fold higher with UH-2B4. This effect was not appreciated previously for DEN-2 (Morens et al., 1987a) . Enhanced DEN-2 production cannot reflect different numbers of available IgG molecules since they were concentration-standardized and since the growth differences must occur over overlapping ranges of antibody concentration. Furthermore, it is monoclonal antibody UH-2B4, which reacts weakly in DEN-2 PRNT (reciprocal titre of 70, compared to >t 2560 for monoclonal antibody 1B 10), that causes the greatest enhancement of DEN-2 production. Conceivably, neutralization at a particular neutralization/enhancement epitope is associated with physical blocking of a viral attachment site by antibody at high concentration, regardless of that antibody's binding properties, whereas enhancement at the same epitope, caused by low dilutions of the same antibody, is more directly dependent upon the antibody's ability to bind to the glycoprotein, regardless of the epitope's proximity to a viral attachment site. This would be consistent with a 'capture effect' of antibody (see below).
That the best DEN-2-enhancing monoclonal antibody (UH-2B4) is DEN-4-derived is of interest in the pathogenesis of DHF and DSS. In Thailand, DHF and DSS are most frequent in children who have previously circulated low-level monotypic antibody to either DEN-1, -3 or -4 and who subsequently become infected with DEN-2 virus (Sangkawibha et al., 1984; Kliks et al., 1989) . Furthermore, an investigation of DEN-2 isolates correlated disease severity with flavivirus group-specific enhancing epitopes detected by DEN-4-derived, but not DEN-2-derived monoclonal antibodies (Morens & Halstead, 1987; Morens et al., 1987c) . We have suggested that the strong association between sequential dengue infections and DHF may reflect ADE of macrophages and monocytes, the only cell types shown to be infected by dengue viruses in vivo.
Although in Thailand DHF is disproportionately associated with DEN-2, elsewhere in South-east Asia other DEN serotypes are implicated. If ADE is involved in DHF pathogenesis, as we and others have proposed, then it would be expected to occur with serotypes other than DEN-2. This study, the first to demonstrate ADE with any dengue virus other than DEN-2, provides consistent evidence. DHF is an important disease in South-east Asia, with nearly 140000 annual cases and 1140 deaths reported to the World Health Organization (1985 data) by the three most highly endemically affected countries of the region (Indonesia, Thailand and Vietnam). These figures are considered marked underestimates of the actual incidence.
Relationship between ADE and other serological parameters
A preliminary DEN-2 study (Morens et al., 1987a) showed that both the monoclonal antibody dilution maximizing DEN-2 ADE and the general shift of the profile along the x-axis of antibody concentration were predicted by the neutralization (NT) titre. Since only two antibody sources were used in these comparison studies, at standardized concentrations, the conclusions cannot be extended to the present data. Among our panel of monoclonal antibodies raised to DEN-4 (Morens et al., 1987b) , UH-2B4 is unique in its dissociation of PRNT from other serological reactivities. Despite a modest PRNT titre (e.g. a reciprocal DEN-4 NT titre of 60), it reacts strongly in HI with DEN-4 haemagglutinins (reciprocal titre of ~> 640) and in ELISA with DEN-4 antigen (reciprocal titre /> 10240). Envelope glycoprotein binding of antibody, rather than NT ability, probably correlates with ADE, but it is clear that NT and ADE reflect interactions between antibodies and single virus epitopes at different antibody: virus ratios. NT and ADE thus cannot be viewed simply as competing effects associated with the binding of different antibodies to different virus epitopes, as has been assumed by other investigators, although this could theoretically happen in an immune serum containing, for example, one monospecific antibody at neutralizing concentration and another at enhancing concentration. If, as has been speculated, NT results from 'multi-hit' kinetics, ADE may be a 'single-hit' or 'few-hit' counterpart. Our preliminary kinetic studies with DEN-2 support this possibility (unpublished results) . If the ADE phenomena described here refect underlying biological processes, they may be helpful in understanding disease pathogenesis. For example, flavivirus ADE, which is thought to occur only in cells having both Fc receptors (FcRs) and virus receptors (Daughaday et al., 1981) , could contribute to cell infection via either a 'capture antibody' effect, in which cell FcRs fix immune complexes containing sparsely coated virions with unbound cell attachment sites, or via a simple opsonic effect, in which sparsely coated virions are more easily uncoated once internalized by cells.
ADE with different DEN serotypes and strains, using different antibodies and m.o.i.
In initial studies with all four DEN serotypes, ADE was produced with two immune monkey sera and with four cord blood sera from naturally immune South-east Asian women, at dilution ranges form 1:320 to 5120 (data not shown). With all four serotypes ADE was detected at an m.o.i, range of 0-0l to 0.25, with and without prior trypsinization of cells to remove virus receptors (Daughaday et al., 1981) and with and without washing of cells after infection to remove unadsorbed virus.
In this study we have described measurable ADE parameters in an established flavivirus system. In comparative ADE studies in P-388D1 murine macrophages infected with each of the four dengue serotypes, pre-incubated with either immune monkey sera, human immune cord blood sera, or dengue monoclonal antibodies directed to ftavivirus group-specific envelope glycoprotein epitopes, we found reproducible, antibody concentration-dependent patterns of enhanced virus production (Fig. 2) . Additional factors that may affect enhancement profiles include inherent virus growth properties, antibody neutralizing (or other serological ability, and antibody-virus binding properties. The reproducible similarity of ADE profiles with four different flaviviruses suggests that it may be possible to define flavivirus ADE in terms of measurable parameters. Because the data are observational in nature, there is no factual basis for asserting that measurable characteristics of ADE with the viruses studied here are applicable to other viruses studied in other systems. Nevertheless, because of the critical need to apply some objective standards to the phenomenon of ADE, we propose the following criteria as guidelines for establishing flavivirus ADE. These criteria, chosen to be sufficiently strict to preclude erroneous ADE claims, include: (i) statistically significant increased production of infectious virions, as measured by quantitative assays, must be documented over most of the cycle of the infected cell and should be of roughly proportional magnitude on sequential assays during the course of infection in culture; (ii) serial dilution of the preincubated antibody source must produce an 'enhancement profile' of rising, peaking and declining production of infectious virions over at least a 103-fold dilution range; (iii) the dilution of the antibody source at which ADE is maximal must be related to its reactivity in other serological tests that measure envelope binding, including NT; (iv) ADE should be detected in the same virus system using, when possible, different antibody sources and virus strains, tested over a range of m.o.i. ; (v) other serum and assay system causes of increased virus production must be ruled out, including a stabilizing or stimulating effect of the antibody source on the infected cell, prevention of thermal decay of virus by antibody, and competition for cell receptors and antibodies by either non-infectious virions or soluble or membrane antigens in the virus stock.
This study provides substantial evidence for all but the last of these five criteria. In many other controlled experiments in our laboratory, however, we have attempted to address the possibility of other mechanisms of infection enhancement. Though use of appropriate negative control sera and washings of cells followed by addition of fresh medium should effectively rule out both stabilizing antibody effects and antibody-prevention of viral decay, it is more difficult to rule out antigenic competition for binding sites. In part because pure preparations of whole infectious virions are difficult or impossible to obtain, we consider that this final criterion is not fully satisfied. Even so, in many uncontrolled studies in our laboratory we have produced nearly identical ADE profiles using viral stock preparations of varying degrees of purity, including freeze/thaw lysates clarified by low-speed centrifugation and infectious virions separated by ultracentrifugation.
Although better understanding of ADE should facilitate study of flavivirus disease pathogenesis, applicability to other viruses must still be determined. Particularly important is HIV, against which vaccines designated to elicit humoral antibody reactive with envelope gp 120 are being produced and tested. Once CD4/FcR-bearing cell systems capable of measuring ADE are developed, it should be possible to study ADE by comparison with the flavivurus experience. Since in at least one case in the flavivirus system enhanced virus production has been noted with core-reactive antibody (Henchal et al., 1985) , the mechanisms of infection enhancement may be multiple or complex. However, these flavivirus ADE criteria can serve as a starting point in obtaining measurable and standardized data from which to compare findings with other agents.
